MSB 6.45% $1.16 mesoblast limited

MSB officially rejected?, page-24

  1. 113 Posts.
    lightbulb Created with Sketch. 8
    Fake news. Wrong place to look at. Here is the evidence.

    Remestemcel-L is application to Center for Biologics Evaluation and Research (CBER).

    https://www.fda.gov/media/141131/download

    The page "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page" is for Center for Drug Evaluation and Research (CDER).

    If you click on search this month you will find this line:
    "Drug Approval Reports by MonthSelect a Report:Reports include only BLAs/NDAs/ANDAs or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER)."


    https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2020-biological-device-application-approvals is the latest CBER approvals.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.16
Change
0.070(6.45%)
Mkt cap ! $1.318B
Open High Low Value Volume
$1.12 $1.20 $1.11 $20.88M 17.94M

Buyers (Bids)

No. Vol. Price($)
5 59978 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 34019 3
View Market Depth
Last trade - 16.10pm 06/05/2024 (20 minute delay) ?
Last
$1.15
  Change
0.070 ( 5.63 %)
Open High Low Volume
$1.12 $1.20 $1.12 3733217
Last updated 15.59pm 06/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.